Genetic and biochemical pathways of β-cell failure in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 11, Issue SUPPL. 4, 2009, Pages 38-45

  Talchai, C ^a   Lin, H V ^a   Kitamura, T ^b   Accili, D ^a  

^a College of Physicians and Surgeons of Columbia University ^*  (United States)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Cell death; Endocrine pancreas; Metabolic disease; Regeneration; Transcription factors

Indexed keywords

GROWTH FACTOR; INSULIN; SULFONYLUREA DERIVATIVE; TRANSCRIPTION FACTOR FKHR;

CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; DIABETOGENESIS; ENDOPLASMIC RETICULUM STRESS; EXPERIMENTAL MODEL; GENOME ANALYSIS; HUMAN; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SYNTHESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT CYCLING; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET DISEASE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL COUNT; CELL PROLIFERATION; CELL SURVIVAL; DIABETES MELLITUS, TYPE 2; HYPERPLASIA; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MICE; SIGNAL TRANSDUCTION;

EID: 70350312488     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01115.x     Document Type: Review

References (66)

1. Accili D. Lilly lecture 2003: the struggle for mastery in insulin action: from triumvirate to republic. Diabetes 2004, 53:1633-1642.
2. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998, 19:477-490.
3. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999, 104:787-794.
4. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998, 15:290-296.
5. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003, 46:3-19.
6. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007, 30:263-269.
7. Grant SF, Thorleifsson G, Reynisdottir I. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006, 38:320-323.
8. Sladek R, Rocheleau G, Rung J. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
9. Scott LJ, Mohlke KL, Bonnycastle LL. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007, 316:1341-1345.
10. Zeggini E, Weedon MN, Lindgren CM. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007, 316:1336-1341.
11. Frayling TM, Timpson NJ, Weedon MN. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007, 316:889-894.
12. Steinthorsdottir V, Thorleifsson G, Reynisdottir I. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 2007, 39:770-775.
13. Kahn SE, Haffner SM, Heise MA. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
14. U.K. Prospective Diabetes Study Group. Diabetes 1995, 44:1249-1258. U.K. Prospective Diabetes Study 16
15. Baggio LL, Drucker DJ. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 2006, 57:265-281.
16. Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001, 414:788-791.
17. O'Rahilly S, Turner RC, Matthews DR. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med 1988, 318:1225-1230.
18. Polonsky KS, Given BD, Hirsch LJ. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988, 318:1231-1239.
19. Leahy JL, Bonner-Weir S, Weir GC. Beta-cell dysfunction induced by chronic hyperglycaemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992, 15:442-455.
20. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
21. Ogilvie RF. A quantitative estimation of the pancreatic islet tissue. Q J Med 1937, 6:287-300.
22. Bruning JC, Winnay J, Bonner-Weir S, Taylor SI, Accili D, Kahn CR. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 1997, 88:561-572.
23. Kido Y, Burks DJ, Withers D. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 2000, 105:199-205.
24. Kido Y, Philippe N, Schaffer AA, Accili D. Genetic modifiers of the insulin resistance phenotype in mice. Diabetes 2000, 49:589-596.
25. Withers DJ, Sanchez-Gutierrez J, Towery H. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998, 391:900-904.
26. Teta M, Long SY, Wartschow LM, Rankin MM, Kushner JA. Very slow turnover of beta-cells in aged adult mice. Diabetes 2005, 54:2557-2567.
27. Magnani M, Rossi L, Stocchi V, Cucchiarini L, Piacentini G, Fornaini G. Effect of age on some properties of mice erythrocytes. Mech Ageing Dev 1988, 42:37-47.
28. Nielsen PJ, Lorenz B, Muller AM. Altered erythrocytes and a leaky block in B-cell development in CD24/HSA-deficient mice. Blood 1997, 89:1058-1067.
29. Okamoto H, Hribal ML, Lin HV, Bennett WR, Ward A, Accili D. Role of the forkhead protein FoxO1 in beta cell compensation to insulin resistance. J Clin Invest 2006, 116:775-782.
30. Okamoto H, Nakae J, Kitamura T, Park BC, Dragatsis I, Accili D. Transgenic rescue of insulin receptor-deficient mice. J Clin Invest 2004, 114:214-223.
31. Moitra J, Mason MM, Olive M. Life without white fat: a transgenic mouse. Genes Dev 1998, 12:3168-3181.
32. Roth SI, Schedewie HK, Herzberg VK, Olefsky JM, Elders MJ, Rubenstein A. Cutaneous manifestations of leprechaunism. Arch Dermatol 1981, 117:531-535.
33. Brissova M, Fowler MJ, Nicholson WE. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem 2005, 53:1087-1097.
34. Freeman HC, Hugill A, Dear NT, Ashcroft FM, Cox RD. Deletion of nicotinamide nucleotide transhydrogenase: a new quantitative trait locus accounting for glucose intolerance in C57BL/6J mice. Diabetes 2006, 55:2153-2156.
35. Bonner-Weir S, Sharma A. Are there pancreatic progenitor cells from which new islets form after birth?. Nature Clinical Practice 2006, 2:240-241.
36. Dor Y, Brown J, Martinez OI, Melton DA. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004, 429:41-46.
37. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008, 10(Suppl. 4):32-42.
38. Souza F, Simpson N, Raffo A. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest 2006, 116:1506-1513.
39. Terauchi Y, Takamoto I, Kubota N. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 2007, 117:246-257.
40. Okada T, Liew CW, Hu J. Insulin receptors in beta-cells are critical for islet compensatory growth response to insulin resistance. Proc Natl Acad Sci U S A 2007, 104:8977-8982.
41. Hashimoto N, Kido Y, Uchida T. Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass. Nat Genet 2006, 38:589-593.
42. Lin X, Taguchi A, Park S. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J Clin Invest 2004, 114:908-916.
43. Weir GC, Bonner-Weir S. A dominant role for glucose in beta cell compensation of insulin resistance. J Clin Invest 2007, 117:81-83.
44. Topp BG, McArthur MD, Finegood DT. Metabolic adaptations to chronic glucose infusion in rats. Diabetologia 2004, 47:1602-1610.
45. Accili D. A kinase in the life of the beta cell. J Clin Invest 2001, 108:1575-1576.
46. Kim JJ, Kido Y, Scherer PE, White MF, Accili D. Analysis of compensatory beta-cell response in mice with combined mutations of Insr and Irs2. Am J Physiol Endocrinol Metab 2007, 292:E1694-E1701.
47. Greenwood RH, Mahler RF, Hales CN. Improvement in insulin secretion in diabetes after diazoxide. Lancet 1976, 1:444-447.
48. Leahy JL, Bumbalo LM, Chen C. Diazoxide causes recovery of beta-cell glucose responsiveness in 90% pancreatectomized diabetic rats. Diabetes 1994, 43:173-179.
49. Ritzel RA, Hansen JB, Veldhuis JD, Butler PC. Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose. J Clin Endocrinol Metab 2004, 89:795-805.
50. Yoshikawa H, Ma Z, Bjorklund A, Grill V. Short-term intermittent exposure to diazoxide improves functional performance of beta-cells in a high-glucose environment. Am J Physiol Endocrinol Metab 2004, 287:E1202-E1208.
51. Hansen JB, Arkhammar PO, Bodvarsdottir TB, Wahl P. Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Current Medicinal Chemistry 2004, 11:1595-1615.
52. Grill V, Bjorklund A. Overstimulation and beta-cell function. Diabetes 2001, 50(Suppl. 1):S122-S124.
53. Weng J, Li Y, Xu W. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008, 371:1753-1760.
54. Kitamura T, Nakae J, Kitamura Y. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest 2002, 110:1839-1847.
55. Buteau J, Spatz ML, Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes 2006, 55:1190-1196.
56. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 2004, 279:42351-42354.
57. Buteau J, Shlien A, Foisy S, Accili D. Metabolic diapause in pancreatic beta-cells expressing a gain-of-function mutant of the forkhead protein Foxo1. J Biol Chem 2007, 282:287-293.
58. Kitamura YI, Kitamura T, Kruse JP. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab 2005, 2:153-163.
59. Xu G, Kaneto H, Laybutt DR. Downregulation of GLP-1 and GIP receptor expression by hyperglycaemia: possible contribution to impaired incretin effects in diabetes. Diabetes 2007, 56:1551-1558.
60. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003, 52:581-587.
61. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006, 116:1802-1812.
62. Martinez SC, Cras-Meneur C, Bernal-Mizrachi E, Permutt MA. Glucose regulates Foxo1 through insulin receptor signaling in the pancreatic islet β-cell. Diabetes 2006, 55:1581-1591.
63. Wrede CE, Dickson LM, Lingohr MK, Briaud I, Rhodes CJ. Protein kinase B/Akt prevents fatty acid-induced apoptosis in pancreatic beta-cells (INS-1). J Biol Chem 2002, 277:49676-49684.
64. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004, 117:421-426.
65. Brunet A, Sweeney LB, Sturgill JF. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
66. Remedi MS, Nichols CG. Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells. PLoS Med 2008, 5:1473-1485.